Intensity Therapeutics (INTS) Preferred Stock Liabilities (2022)
Intensity Therapeutics' (INTS) quarterly Preferred Stock Liabilities came in at $10.0 million in Q4 2022.
Intensity Therapeutics (INTS) Preferred Stock Liabilities (2022) Analysis & Trends
Intensity Therapeutics (INTS) has 1 years of Preferred Stock Liabilities data on file, last reported at $10.0 million in Q4 2022.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $10.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $10.0 million (changed N/A YoY) and the FY2022 annual result came in at $10.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $10.0 million in Q4 2022.
- In the past five years, Preferred Stock Liabilities ranged from a high of $10.0 million in Q4 2022 to a low of $10.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 10.00 Mn |